TMED7

Across TCGA pan-cancer cohorts, TMED7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMED7 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMED7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMED7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where TMED7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.605	1.000	.001	21	view →
UCEC	OS	Median	II,III,IV	0.429	1.000	.044	4	view →
PDAC	OS	Tertile	II,III,IV	0.750	0.508	.018	4	view →
LUAD	DFS	Median	II,III,IV	0.222	0.836	.011	2	view →
HNSC	OS	Tertile	III,IV	0.793	0.559	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMED7–CCRCC (OS)

Open the CCRCC breakdown →